Literature DB >> 14711728

Histopathology of eyes enucleated after endoresection of choroidal melanoma.

Peter W Hadden1, Paul S Hiscott, Bertil E Damato.   

Abstract

PURPOSE: To demonstrate the histopathologic features of eyes enucleated after endoresection for choroidal melanoma to assess the complications of this treatment and to determine indications for further treatment after endoresection in the setting of possible tumor recurrence.
DESIGN: Retrospective, observational case series. PARTICIPANTS: Sixty-one consecutive patients who had undergone endoresection for uveal melanoma.
METHODS: Eyes that had undergone enucleation after endoresection were identified, and their charts and histologic characteristics were reviewed. Pertinent features were described. One patient was excluded because enucleation was performed as a primary treatment when endoresection was abandoned at the time of his initial treatment. MAIN OUTCOME MEASURES: The outcome measures included: reasons for enucleation; tumor recurrence; and location, clinical, and histologic characteristics of each recurrence.
RESULTS: Twelve eyes were identified that had undergone enucleation after endoresection. The reasons for enucleation were: (1) local tumor recurrence detected by ophthalmoscopy (2 patients) or echography (1 patient); (2) opaque media preventing adequate ophthalmoscopy (4 patients); (3) blind and painful eye of uncertain cause (1 patient); and (4) a combination of blind eye and limited fundus view (4 patients), which was the result of untreatable retinal detachment (3 patients) and endophthalmitis (1 patient). Eight of 12 patients had recurrent choroidal melanoma. Recurrences were all located adjacent to the resection site, although in 1 patient there was extensive diffuse recurrence throughout the eye. The recurrence was visible clinically in 3 patients and obscured because of opaque media (2 patients), a combination of inadequate echography and retinal detachment (1 patient), retinal detachment (1 patient), and endophthalmitis (1 patient).
CONCLUSIONS: Recurrent disease occurred at the site of the primary tumor with no seeding except in 1 patient, whose marginal recurrence was not immediately detected and treated because of opaque media. As with other treatments conserving the eye, enucleation should be performed if adequate ocular examination is not possible, and follow-up should be lifelong.

Entities:  

Mesh:

Year:  2004        PMID: 14711728     DOI: 10.1016/j.ophtha.2003.05.007

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  8 in total

1.  Progress in the management of patients with uveal melanoma. The 2012 Ashton Lecture.

Authors:  B Damato
Journal:  Eye (Lond)       Date:  2012-06-29       Impact factor: 3.775

2.  Core Endoresection as Neoadjuvant Treatment of Uveal Melanoma.

Authors:  Iwona Rospond-Kubiak; Carl Groenewald; Sarah E Coupland; Bertil Damato
Journal:  Ocul Oncol Pathol       Date:  2015-09-24

3.  Secondary endoresection for previously treated choroidal melanomas with a non-responsive course and persistent exudative retinal detachment.

Authors:  Ahmet Kaan Gündüz; Ibadulla Mirzayev
Journal:  Int J Ophthalmol       Date:  2022-02-18       Impact factor: 1.779

4.  Initial results of fractionated CyberKnife radiosurgery for uveal melanoma.

Authors:  Faruk Zorlu; Ugur Selek; Hayyam Kiratli
Journal:  J Neurooncol       Date:  2009-02-22       Impact factor: 4.130

5.  Exoresection and endoresection for uveal melanoma.

Authors:  Kaan Gündüz; Nikolaos E Bechrakis
Journal:  Middle East Afr J Ophthalmol       Date:  2010-07

6.  Outcomes of primary endoresection for choroidal melanoma.

Authors:  Andre A C Vidoris; Andre Maia; Marcia Lowen; Melina Morales; Jordan Isenberg; Bruno F Fernandes; Rubens N Belfort
Journal:  Int J Retina Vitreous       Date:  2017-11-06

Review 7.  Choroidal Melanoma Resection.

Authors:  Hany S Hamza; Abdelrahman M Elhusseiny
Journal:  Middle East Afr J Ophthalmol       Date:  2018 Apr-Jun

8.  Surgical Approach in Intraocular Tumors

Authors:  Ahmet Kaan Gündüz; Ibadulla Mirzayev
Journal:  Turk J Ophthalmol       Date:  2022-04-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.